5- (5,6- dimethoxy- 1H- benzimidazol- 1- yl)- 3- ((2- (trifluoromethyl)benzyl)oxy)thiophene- 2- carboxamide

a polo-like kinase 1 inhibitor; structure in first source

Also Known As:

DBTBOT-carboxamide; GW843682X

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-(trifluoromethyl)benzyl)oxy)thiophene-2-carboxamide: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-(trifluoromethyl)benzyl)oxy)thiophene-2-carboxamide: 5
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-(trifluoromethyl)benzyl)oxy)thiophene-2-carboxamide: 5

Experts

1.	Chu, Yuxin: 1 article (01/2016)
2.	Hu, Qinyong: 1 article (01/2016)
3.	Hu, Weiguo: 1 article (01/2016)
4.	Peng, Min: 1 article (01/2016)
5.	Song, Qibin: 1 article (01/2016)
6.	Brassesco, María Sol: 1 article (07/2013)
7.	Francisco de Oliveira, Harley: 1 article (07/2013)
8.	Morales, Andressa Gois: 1 article (07/2013)
9.	Pezuk, Julia Alejandra: 1 article (07/2013)
10.	Roberto, Gabriela Molinari: 1 article (07/2013)

Related Diseases

1.	Nasopharyngeal Carcinoma 01/01/2016 - "These findings indicated that GW843682X exhibited remarkable cytotoxic effects on nasopharyngeal carcinoma 5-8F cells by down-regulating IAP gene expression, suggesting that GW843682X may become a novel therapeutic agent for nasopharyngeal carcinoma." 01/01/2016 - "In this study, the cytotoxic effect of GW843682X was investigated on cell proliferation, cell cycle and apoptosis of nasopharyngeal carcinoma 5-8F cells. " 01/01/2016 - "The cytotoxic effect of GW843682X on nasopharyngeal carcinoma."
2.	Carcinoma (Carcinomatosis) 07/01/2013 - "In the present study we tested and compared the in vitro antitumor activities of four different inhibitors of Polo-like kinase 1 (PLK1) (BI 2536, BI 6727, GW843682X, and GSK461364), against 3 bladder carcinoma cell lines RT4, 5637 and T24. "
3.	Neoplasms (Cancer) 07/01/2011 - "GW843682X showed considerable toxicity against a panel of paediatric tumour cell lines suggesting that PLK1 inhibitors under clinical development should be evaluated against paediatric malignancies too." 01/01/2016 - "GW843682X is a publicly available anti-cancer compound by inhibiting Polo-like kinase. " 07/01/2011 - "An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies." 01/01/2016 - "Interestingly, GW843682X signiﬁcantly inhibited the mRNA expression of IAP-1 and survivin, which function as key regulators of mitosis and programmed cell death, and is overexpressed in many tumor types. "
4.	Osteosarcoma (Osteogenic Sarcoma) 07/01/2011 - "Apart from the N-Myc-amplified neuroblastoma cell lines, the osteosarcoma cell lines MNNG-HOS and OST, which are highly resistant to standard anticancer drugs, were sensitive to GW843682X. "
5.	Neuroblastoma 07/01/2011 - "Apart from the N-Myc-amplified neuroblastoma cell lines, the osteosarcoma cell lines MNNG-HOS and OST, which are highly resistant to standard anticancer drugs, were sensitive to GW843682X. "

Related Drugs and Biologics

1.	Polo-Like Kinase 1
2.	GSK 461364
3.	BI 6727
4.	BI 2536
5.	Phosphotransferases (Kinase)
6.	Caspases
7.	Messenger RNA (mRNA)
8.	Methylnitronitrosoguanidine (MNNG)
9.	Survivin
10.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone